IP Library Granted Patent US 10,478,498
Granted Patent B2
US 10,478,498 · App. 15/331,197 · Granted Nov 19, 2019

Excipient compounds for biopolymer formulations

Inventors: David S. Soane (Palm Beach, FL); Philip Wuthrich (Watertown, MA); Rosa Casado Portilla (Middleton, MA); Robert P. Mahoney (Newbury, MA); Mark Moody (Concord, MA); Daniel G. Greene (Belmont, MA)
Assignee: REFORM BIOLOGICS, LLC
A61K39/39591A61K47/12A61K47/22C07K16/22C07K16/241C07K16/32
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,478,498
App. No.
15/331,197
Granted
Nov 19, 2019
Kind
B2
Abstract

The invention encompasses formulations and methods for the production thereof that permit the delivery of concentrated protein solutions. The inventive methods can yield a lower viscosity liquid protein formulation or a higher concentration of therapeutic or nontherapeutic proteins in the liquid formulation, as compared to traditional protein solutions. The inventive methods can also yield a higher stability of a liquid protein formulation.

Claims (11)

1. An injectable, liquid pharmaceutical formulation comprising at least about 100 mg/ml therapeutic protein and a viscosity-reducing amount of caffeine, wherein the viscosity-reducing amount of caffeine is about 15 mg/ml or less, and wherein the formulation further comprises niacinamide, and

wherein the viscosity of the formulation is at least about 30% less than the viscosity of a control formulation, wherein the control formulation does not contain caffeine but is otherwise identical on a dry weight basis to the liquid pharmaceutical formulation.

2. The formulation of claim 1 , wherein the therapeutic protein is an antibody.

3. The formulation of claim 1 , wherein the therapeutic protein is selected from the group consisting of bevacizumab, trastuzumab, adalimumab, infliximab, etanercept, darbepoetin alfa, epoetin alfa, cetuximab, pegfilgrastim, filgrastim, and rituximab.

4. The formulation of claim 1 , wherein the viscosity of the formulation is at least about 50% less than the viscosity of the control formulation.

5. The formulation of claim 1 , wherein the viscosity is less than about 20 cP.

6. The formulation of claim 5 , wherein the viscosity is less than about 10 cP.

7. The formulation of claim 1 , wherein the formulation contains at least about 200 mg/mL of the therapeutic protein.

8. The formulation of claim 1 , wherein the viscosity-reducing amount of caffeine is about 15 mg/ml.

9. The formulation of claim 8 , wherein the amount of niacinamide is about 15 mg/ml.

10. The formulation of claim 7 , wherein the therapeutic protein is an antibody.

Assignments (3)
CHANGE OF NAME Recorded Feb 16, 2022
From: REFORM BIOLOGICS, INC.
To: COMERA LIFE SCIENCES, INC.
Reel/Frame 059327/0985 →
CONVERSION FROM A LIMITED LIABILITY COMPANY TO A CORPORATION Recorded Jul 7, 2021
From: REFORM BIOLOGICS, LLC
To: REFORM BIOLOGICS, INC.
Reel/Frame 056784/0447 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jan 12, 2017
From: SOANE, DAVID S.; WUTHRICH, PHILIP; PORTILLA, ROSA CASADO; MAHONEY, ROBERT P.; MOODY, MARK; GREENE, DANIEL G.
To: REFORM BIOLOGICS, LLC
Reel/Frame 041349/0382 →
Continuity (7)
Continuation In Part 14966549 · Dec 11, 2015
Continuation 14744847 · Jun 19, 2015
Provisional Application 62014784 · Jun 20, 2014
Provisional Application 62083623 · Nov 24, 2014
Provisional Application 62136763 · Mar 23, 2015
Provisional Application 62245513 · Oct 23, 2015
Related Publication 20170232103A1 · Aug 17, 2017
Cited By (1)
US 12,350,340